Leading German research university in neuroscience, RNA therapeutics, and clinical trials, with strong ERC track record and translational medicine platforms.
The University of Tübingen is a major German research university with deep strength in neuroscience, vision research, biomedical sciences, and RNA-based therapeutics. It runs large clinical trials (e.g., neuroprotection in Parkinson's, neonatal brain injury) and develops advanced biological platforms like organ-on-a-chip systems and gene editing tools. Beyond life sciences, it contributes to European research data infrastructure, social science research on migration, and human-machine interaction. With 52 coordinated H2020 projects and over EUR 96 million in EC funding, it operates as both a scientific powerhouse and a reliable consortium anchor.
Leads switchBoard (retinal processing), LUMINOUS (consciousness), ALBINO (neonatal brain injury), plus projects on blindness, photoreceptor degeneration, retina organoids, sleep, and neuroprotection.
Coordinated RNArepair (site-directed RNA editing) and BREATHE (mRNA-based gene correction for inherited diseases), alongside cancer genomics projects like ALKATRAS and CholangioConcept.
Runs multi-centre trials including FAIR-PARK-II (Parkinson's iron chelation), ALBINO (neonatal neuroprotection), REGAIN (hearing regeneration), and Ebola vaccine studies (VSV-EBOVAC, VSV-EBOPLUS).
Participates in EUDAT2020, CLARIN-PLUS, and multiple research infrastructure projects; recent keywords show strong FAIR and open science engagement.
Recent keyword clusters around migration, refugees, and Islam indicate growing involvement in social science research beyond their traditional biomedical core.
CogIMon (cognitive interaction in motion), AIDE (robotic exoskeletons for disabled people), and recent work on neural-machine interfaces and brain stimulation.
In the early H2020 period (2015–2018), Tübingen focused heavily on fundamental neuroscience, Parkinson's disease research, clinical drug trials, and assistive robotics — keywords like neuroprotection, transcriptomics, iron chelation, and robotic exoskeletons dominated. From 2019 onward, the university shifted toward translational platforms (organ-on-a-chip, drug development), digital methods (machine learning, neural-machine interfaces), and research policy topics (open science, FAIR data, research infrastructure). A notable addition is social science research on migration, absent from the early portfolio entirely.
Tübingen is moving from bench research toward translational applications (organ-on-chip, machine learning in medicine) and research infrastructure governance — expect future projects to bridge lab science with digital tools and data-sharing frameworks.
Tübingen balances leadership and partnership well: it coordinates 36% of its projects (52 of 145), a high rate for a university, while also joining large consortia as a specialist contributor. With 1,072 unique consortium partners across 69 countries, it operates as a genuine network hub rather than relying on a small circle of repeat collaborators. Its strong ERC portfolio (32 grants) shows it attracts top individual researchers who then pull in diverse international teams.
One of the most connected H2020 universities, with 1,072 unique partners spanning 69 countries. The network is heavily European but extends globally, with particular density in Western European biomedical research hubs and emerging connections in social science domains.
Tübingen combines world-class neuroscience and vision research with strong RNA therapeutics capability and clinical trial infrastructure — a rare combination that lets it take discoveries from molecular biology through to patient studies within a single institution. Its 32 ERC grants signal exceptional individual talent, making it a magnet for ambitious researchers. For consortium builders, Tübingen offers both scientific depth and operational maturity: it can lead complex multi-centre projects and has the administrative capacity to manage large EC budgets.
